Prognosis and Treatment of Wilms’ Tumor

R. Mastrangelo
DOI: https://doi.org/10.1177/030089166505100101
1965-01-01
Tumori
Abstract:The paper reviews the prognosis and the program of treatment for Wilms’ tumor. Without therapy the disease is invariably fatal. Prognosis in treated cases is influenced by the type and the method of treatment as well as by the age of the patients and the anatomical extent of the disease. The overall survival is around 25 percent. For small and incapsulated tumors in patients of less than 18 months of age the treatment of choice is surgery and actinomycin D and prophylactic courses of actinomycin D every 2–3 months during the first year. The 2 year survival may range from 80 to 50 percent. For large and non incapsulated tumors in patients with more than 18 months of age and patients with extensive and not incapsulated tumor at any age, the treatment of choice is surgery preceded and followed by radiation therapy (1000 r and 3000 r respectively). Actinomycin D is administered soon after surgery and then prophylactically every 2–3 months during the first year. The 2-year survival may range from 50 to 10 percent. In presence of pulmonary metastases actinomycin D and radiotherapy are recommanded. In case of an isolated lung metastasis persisting for some time thoracotomy is advised. The 2-year survival is less than 10 percent. Patients with intra-abdominal recurrences should receive courses with actinomycin D and radiation therapy, after exploratory laparotomy but in these cases the 2-year survival rarely exceeds 1 percent.
What problem does this paper attempt to address?